Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Present with type 2 diabetes mellitus~* Have been taking metformin and/or pioglitazone~* Have received treatment with basal insulin glargine, injected once a day, for greater than or equal to 90 days~* Have glycosylated hemoglobin A1c (HbA1c) concentration between greater than or equal to 7.5% and less than or equal to 10.5~* Have a fasting plasma glucose concentration of less than or equal to 6.7 millimoles per liter \[mmol/L, less than or equal to 121 milligrams per deciliter (mg/dL)\], or greater than 6.7 mmol/L (greater than 121 mg/dL) if the investigator considers that further titration of basal insulin glargine is not possible for safety reasons~* Not pregnant or breastfeeding~Exclusion Criteria:~* Have Type 1 Diabetes~* Their stable dose of pioglitazone is greater than the maximum dose approved for use in combination with insulin in their country~* Have a body mass index (BMI) greater than 45 kilograms per square meter (kg/m2).~* Have a history of scheduled mealtime (prandial) insulin use within 12 weeks of the screening visit and the total duration of the prandial insulin treatment was greater than 2 weeks~* Have had more than one episode of severe hypoglycaemia within 24 weeks prior to entry into the study~* Have cardiac disease with a functional status that is Class III or IV~* Have a history of renal or liver disease~* Have had a blood transfusion or have a blood disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Insulin lispro low mixture (LM) (Type: EXPERIMENTAL): Two daily injections (breakfast and dinner) of insulin lispro mix 75/25
- Insulin glargine+insulin lispro (Type: ACTIVE_COMPARATOR): Once-daily (bedtime) basal insulin glargine and once-daily (before the main meal with the highest average 2-hour postprandial blood glucose concentration) prandial insulin lispro

Based on this trial design, predict the completion outcome and termination type (if applicable).